Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

An article by Bloomberg News claims that the cath lab at Mount Sinai Hospital in New York City has sent patients with previously scheduled appointments through its emergency department (ED), a practice that may allow for uninsured patients’ costs to be covered. The hospital has not been accused of any wrong-doing and hospital officials said they are reviewing issues related to the allegations.

OrbusNeich today announced that patient enrollment has been initiated in Japan in the pivotal clinical trial of the COMBO Dual Therapy Stent(tm) (COMBO Stent) employing a single Japan-U.S. protocol conducted as a Global Clinical Trial "proof-of-concept" under the framework of the joint Japan-U.S. Harmonization-By-Doing [HBD] initiative. The first patient was enrolled at Shonan Kamakura General Hospital, Japan, by Dr. Shigeru Saito, M.D., the vice director of the hospital and co-principal investigator of the study.

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that in addition to a talk focusing on robotics in the future of the cath lab, cases submitted by users of its CorPath Vascular Robotics System have been accepted for presentation at the Cardiovascular Research Technologies (CRT) conference on February 22 – 25, 2014 in Washington, D.C.

The interventional cardiology team led by Ehtisham Mahmud, MD, FACC, at UC San Diego Sulpizio Cardiovascular Center (SCVC) has successfully completed the first two robotically-assisted coronary angioplasty/stent procedures in California. Patients with coronary artery disease (CAD) now have access to this new technology that puts the precision of a robot in the hands of interventional cardiologists during procedures to open clogged heart arteries.

Boston Scientific Corporation (NYSE: BSX) announces the appointment of Craig Thompson, M.D., as senior vice president and chief medical officer, Interventional Cardiology, effective immediately.  Dr. Thompson, a global leader in complex cardiac interventions, will play a key role in driving the development of innovative medical solutions within the Boston Scientific Interventional Cardiology business.

Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the launch of the Bifurcation Institute. The Bifurcation Institute is a comprehensive education resource established to advance the standard of care for bifurcated coronary artery disease, a common, and often untreated, clinical need.